(0.26%) 5 113.05 points
(0.36%) 38 376 points
(0.30%) 15 976 points
(-1.34%) $82.73
(6.34%) $2.05
(-0.07%) $2 345.50
(-0.22%) $27.48
(3.92%) $958.25
(-0.22%) $0.933
(-0.33%) $10.99
(-0.54%) $0.796
(1.65%) $93.39
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.28%
8.86% $ 19.79
@ $21.69
Ausgestellt: 14 Feb 2024 @ 15:30
Rendite: -8.76%
Vorheriges Signal: Feb 13 - 15:30
Vorheriges Signal:
Rendite: -1.99 %
Live Chart Being Loaded With Signals
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally...
Stats | |
---|---|
Tagesvolumen | 983 157 |
Durchschnittsvolumen | 616 151 |
Marktkapitalisierung | 1.78B |
EPS | $0 ( 2024-02-27 ) |
Nächstes Ertragsdatum | ( $-0.110 ) 2024-05-01 |
Last Dividend | $1.750 ( 2009-07-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.22 |
ATR14 | $0.0210 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-14 | Muzzey Dale | Sell | 940 | Common Stock |
2024-04-14 | Verratti Mark | Sell | 1 076 | Common Stock |
2024-04-06 | Munk Natalie | Sell | 581 | Common Stock |
2024-03-14 | Leffler Scott J. | Buy | 46 905 | Common Stock |
2024-03-25 | Munk Natalie | Sell | 363 | Common Stock |
INSIDER POWER |
---|
52.41 |
Last 96 transactions |
Buy: 1 118 283 | Sell: 407 342 |
Volumen Korrelation
Myriad Genetics Inc Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Myriad Genetics Inc Korrelation - Währung/Rohstoff
Myriad Genetics Inc Finanzdaten
Annual | 2022 |
Umsatz: | $678.40M |
Bruttogewinn: | $476.40M (70.22 %) |
EPS: | $-1.390 |
FY | 2022 |
Umsatz: | $678.40M |
Bruttogewinn: | $476.40M (70.22 %) |
EPS: | $-1.390 |
FY | 2021 |
Umsatz: | $690.60M |
Bruttogewinn: | $493.00M (71.39 %) |
EPS: | $-0.350 |
FY | 2020 |
Umsatz: | $638.60M |
Bruttogewinn: | $452.50M (70.86 %) |
EPS: | $-2.69 |
Financial Reports:
No articles found.
Myriad Genetics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $1.750 | 2009-06-15 |
Last Dividend | $1.750 | 2009-07-01 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $3.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.02 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $3.50 | 10.20% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.374 | 1.500 | -7.47 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.239 | 1.200 | -7.96 | -9.55 | [0 - 0.3] |
returnOnEquityTTM | -0.350 | 1.500 | -5.00 | -7.49 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.268 | 0.800 | 8.66 | 6.93 | [1 - 3] |
quickRatioTTM | 0.963 | 0.800 | 9.04 | 7.23 | [0.8 - 2.5] |
cashRatioTTM | 0.363 | 1.500 | 9.09 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.175 | -1.500 | 7.08 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -93.79 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.782 | 2.00 | -0.261 | -0.521 | [0 - 30] |
freeCashFlowPerShareTTM | -1.692 | 2.00 | -0.846 | -1.692 | [0 - 20] |
debtEquityRatioTTM | 0.295 | -1.500 | 8.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.689 | 1.000 | 1.852 | 1.852 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.370 | 1.000 | -9.41 | -9.41 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.317 | 1.000 | -2.87 | -2.87 | [0.2 - 2] |
assetTurnoverTTM | 0.639 | 0.800 | 9.07 | 7.26 | [0.5 - 2] |
Total Score | -0.0149 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.42 | 1.000 | -0.648 | 0 | [1 - 100] |
returnOnEquityTTM | -0.350 | 2.50 | -3.21 | -7.49 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.692 | 2.00 | -0.564 | -1.692 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.782 | 2.00 | -0.261 | -0.521 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.289 | 1.500 | -5.26 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0870 | 1.000 | -4.68 | 0 | [0.1 - 0.5] |
Total Score | -2.29 |
Myriad Genetics Inc
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.